Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS31905 plus chemotherapy as first-line treatment for CLDN18.2-positive advanced solid tumors
CTR20232981Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Feb 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QLS-31905 in Non-hematologic malignancy, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma (PDAC), biliary cancer, sponsored by Qilu Pharmaceutical. Started Feb 2024; status: active.
02
Drugs
QLS-31905
03
Conditions
Non-hematologic malignancygastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic adenocarcinoma (PDAC)biliary cancer
Beyond the preview
Go deeper on CTR20232981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232981.